儿童急性淋巴细胞白血病成功治疗后的肥胖问题。
Obesity after successful treatment of acute lymphoblastic leukemia in childhood.
作者信息
Van Dongen-Melman J E, Hokken-Koelega A C, Hählen K, De Groot A, Tromp C G, Egeler R M
机构信息
Department of Child and Adolescent Psychiatry, Sophia Children's Hospital/Erasmus University, Rotterdam, The Netherlands.
出版信息
Pediatr Res. 1995 Jul;38(1):86-90. doi: 10.1203/00006450-199507000-00015.
Early and late effects of treatment for acute lymphoblastic leukemia (ALL) on weight was retrospectively investigated in 113 children in continuous first remission. Weight was examined at diagnosis up to 10 y after cessation of treatment. There was an increased prevalence of overweight after treatment for ALL which persisted over time. All treatment regimens included corticosteroid therapy, and 52 patients received additional cranial irradiation. Patients treated with and without cranial irradiation did not differ in weight gain, indicating that not cranial irradiation but corticosteroid therapy might explain weight gain in children treated for ALL. Dexamethasone was associated with a significant increase of weight at cessation of treatment. Patients treated with a combination of prednisone and dexamethasone had as a late effect the highest prevalence of obesity (44%). Gender or age at diagnosis were not related to weight gain.
对113名处于首次持续完全缓解期的儿童进行回顾性研究，以调查急性淋巴细胞白血病（ALL）治疗的早期和晚期对体重的影响。在诊断时直至治疗停止后10年对体重进行检查。ALL治疗后超重的患病率增加，且这种情况持续存在。所有治疗方案均包括皮质类固醇治疗，52例患者接受了额外的颅脑照射。接受和未接受颅脑照射的患者在体重增加方面没有差异，这表明并非颅脑照射而是皮质类固醇治疗可能解释了ALL治疗儿童的体重增加。地塞米松与治疗停止时体重显著增加有关。接受泼尼松和地塞米松联合治疗的患者作为晚期效应肥胖患病率最高（44%）。诊断时的性别或年龄与体重增加无关。
Zotero 插件